Rat anti Human C3g antibody, clone 9,
(also known as clone YB2/90-5-20) recognizes a neoantigen in the C3g region of C3 and also recognizes the fragments iC3, iC3b and C3dg. There are 3 activation pathways within the complement system; the classical, lectin and alternative pathways. C3 is the key component of all 3, with all of them converging on C3, resulting in its activation and cleavage to the anaphylatoxin C3a and the opsonin C3b (Ricklin et al. 2016
). C3b targets microbial cell surface receptors, enhancing phagocytosis (Fries et al. 1987
). However, C3b is not stable in serum and is rapidly cleaved by factor I and a cofactor to form the more stable fragment iC3b (inactivated C3b) and C3f. iC3b is then slowly cleaved to form C3c, C3dg and C3f (Ricklin et al. 2016
). Other proteases in vitro have been shown to cleave Cdg into C3d and C3g; however this has not been observed in vivo
and thus is not thought to occur naturally (Lachmann et al. 1982
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Applications of C3g antibody
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.